New FDA label extension broadens Sanofi’s Tzield use in type 1 diabetes care

Sanofi’s Tzield (teplizumab-mzwv) just gained a key US label extension: the FDA has now approved the monoclonal antibody to delay loss of insulin production in children 8-17 already at stage 3 type 1 diabetes, adding to its earlier prevention-focused indication.

Edited by ad hoc news Flagship & Bestseller Desk. Reviewed before publication on 06/15/2026 at 11:52 AM ET. Details in the imprint.

Sanofi’s Tzield, the first disease-modifying therapy in type 1 diabetes, has just secured a fresh US approval that shifts it from a pure prevention play into everyday treatment practice for some newly diagnosed patients. The Food and Drug Administration has granted accelerated approval for Tzield (teplizumab-mzwv) to delay the decline of a child’s own insulin production in 8- to 17-year-olds who are already in stage 3 type 1 diabetes, a notable expansion beyond its earlier use in high-risk but not yet fully diabetic individuals. According to Sanofi’s latest press release, this label extension follows new data showing preserved C-peptide levels over time.

How Tzield works and what the new indication changes

Unlike traditional insulin therapies that replace the hormone once pancreatic beta cells are largely lost, Tzield is a CD3-directed monoclonal antibody designed to modulate the immune system’s attack on those insulin-producing cells. By binding to CD3 on T cells, the drug is thought to reduce the autoimmune activity driving type 1 diabetes, helping preserve remaining beta cell function and thus endogenous insulin production in eligible patients. Sanofi notes that Tzield is given as a series of daily infusions over a 14-day course, and that treatment is not intended for people with non-autoimmune forms of dysglycemia or type 2 diabetes. The company’s detailed announcement explains that in the pivotal study, treated children showed a slower decline in C-peptide, a marker of endogenous insulin, compared with placebo.

The newly granted stage 3 indication builds on an earlier US approval from November 2022, when the FDA cleared Tzield to delay the onset of stage 3 type 1 diabetes in adults and children aged 8 years and older with stage 2 disease, a group characterized by autoantibodies and abnormal glucose but not yet full-blown clinical diabetes. That preventive label was broadened again in April 2026 to include children from 1 year of age in the stage 2 setting. Outside the United States, Tzield - marketed under the name Tezeild in parts of Europe - has received approvals to delay progression to stage 3 in several regions, including the UK, EU, China, Australia, Canada, Israel, Saudi Arabia, the UAE, Kuwait, Brazil and Switzerland, underscoring Sanofi’s global ambition for the franchise. Independent industry coverage has highlighted that this product now anchors Sanofi’s immunology push in diabetes, a field where disease-modifying options have historically been absent. A recent regulatory news summary notes that the latest US decision positions Tzield as a unique option to slow beta cell decline in recently diagnosed pediatric patients.

For endocrinologists and diabetes centers, the practical impact is that Tzield moves closer to the start of standard care pathways. Children in the 8-17 age bracket who have just been diagnosed with stage 3 autoimmune type 1 diabetes - and who meet the inclusion criteria - could receive the short infusion course relatively early, alongside insulin and education, with the goal of maintaining residual insulin secretion for longer. Clinically, better preservation of C-peptide has been associated in earlier research with improved glycemic control and potentially a reduced risk of severe hypoglycemia, though individual outcomes vary and long-term real-world data will take time to mature. The accelerated-approval pathway also means Sanofi must provide confirmatory evidence that the observed biomarker benefit translates into durable clinical advantages; if not, regulators can revisit the label.

Strategically, Tzield is a flagship asset for Sanofi’s shift away from a dependence on older diabetes blockbusters and toward more targeted, immunology-driven therapies across multiple diseases. Management has repeatedly flagged Tzield as one of the company’s important growth drivers in specialty care, even if it will never match the volumes of basal insulin in general practice. At the same time, the company continues to operate a broad vaccines and consumer health portfolio, which helps balance the inherently narrower patient populations for precision biologics. Sanofi is publicly listed in Europe, with its primary trading line on Euronext Paris, and also maintains US listings via American depositary receipts.

Sanofi’s Tzield in brief: key product facts

• Product: Tzield (teplizumab-mzwv)
• Manufacturer: Sanofi
• Category: Flagship disease-modifying biologic for type 1 diabetes
• Launch date: First US approval November 2022 (stage 2 T1D); latest US label extension for stage 3 children June 2026
• MSRP / Price: Pricing not officially detailed in the latest announcement; reimbursement subject to payer negotiations and insurance coverage in the US
• Availability: Prescription-only, administered as a 14-day infusion course in specialized diabetes centers and hospitals in the US and other approved markets
• Target audience: Children and adolescents at risk of, or recently diagnosed with, autoimmune type 1 diabetes who meet the labeled criteria
• Key differentiator / USP: First and currently only FDA-approved therapy that aims to modify the underlying autoimmune process in type 1 diabetes rather than simply replace lost insulin

This article was a.i.-assisted and editorially reviewed. Product information without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Trading involves risk up to and including the total loss of invested capital.